Alisha Holtzhausen

List of Publications by Year
in descending order

21 papers	1,161 citations	687363 13 h-index	940533 16 g-index
21 all docs	21 docs citations	21 times ranked	2072 citing authors

#	Article	IF	Citations
1	Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. Cell Reports, 2021, 35, 109071.	6.4	35
2	Overcoming Immunotherapy Resistance by Targeting the Tumor-Intrinsic NLRP3-HSP70 Signaling Axis. Cancers, 2021, 13, 4753.	3.7	9
3	A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to antiâ€“PD-1 immunotherapy. Journal of Clinical Investigation, 2020, 130, 2570-2586.	8.2	134
4	TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Antiâ€“PD-1 Therapy in Melanoma. Cancer Immunology Research, 2019, 7, 1672-1686.	3.4	85
5	MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression. Nature Communications, 2019, 10, 1515.	12.8	25
6	Paracrine Wnt5a-Î²-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization. Immunity, 2018, 48, 147-160.e7.	14.3	185
7	Stromal Fibroblasts Mediate Antiâ€“PD-1 Resistance via MMP-9 and Dictate TGFÎ² Inhibitor Sequencing in Melanoma. Cancer Immunology Research, 2018, 6, 1459-1471.	3.4	81
8	Factor XIIIAâ€”expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking. Nature Communications, 2018, 9, 1988.	12.8	69
9	Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. Journal of Clinical Investigation, 2018, 128, 2356-2369.	8.2	118
10	Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. Cancer Immunology Research, 2015, 3, 1082-1095.	3.4	147
11	Targeting the Wnt5a-Î²-catenin pathway in the melanoma microenvironment to augment checkpoint inhibitor immunotherapy.. Journal of Clinical Oncology, 2015, 33, 3054-3054.	1.6	2
12	Early Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy. Frontiers in Immunology, 2014, 5, 438.	4.8	12
13	Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development. FASEB Journal, 2014, 28, 1248-1267.	0.5	80
14	Combinatorial TGF-Î² signaling blockade and anti-CTLA-4 antibody immunotherapy in a murine BRAF^{V600E}-PTEN-/- transgenic model of melanoma.. Journal of Clinical Oncology, 2014, 32, 3011-3011.	1.6	25
15	Role of the Wnt-Î²-catenin signaling pathway in melanoma-mediated dendritic cell tolerization. , 2013, 1, P153.		3
16	Type III TGF-Î² receptor downregulation generates an immunotolerant tumor microenvironment. Journal of Clinical Investigation, 2013, 123, 3925-3940.	8.2	94
17	Abstract 3548: Loss of the type III TGF-Î² receptor during cancer progression generates an immunotolerant tumor microenvironment: Translational implications for TGF-Î² inhibition and immunotherapy biomarker development. , 2012, , .		0
18	Abstract 3035: Bone morphogenetic proteins signal through Smad2 and Smad3 to regulate cell migration and proliferation. , 2012, , .		0

#	Article	IF	Citations
19	Type III TGF-Î² Receptor Enhances Colon Cancer Cell Migration and Anchorage-Independent Growth. Neoplasia, 2011, 13, 758-IN28.	5.3	56
20	Abstract 3972: The role of the TGF-Î² type III receptor in colon carcinogenesis. , 2010, , .		0
21	Identification of a Germline Pyrin Variant in a Metastatic Melanoma Patient With Multiple Spontaneous Regressions and Immune-related Adverse Events. Journal of Immunotherapy, 0, Publish Ahead of Print, .	2.4	1